A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1

• Published in: Gan to kagaku ryoho Vol. 32; no. 5; p. 663
• Main Authors: Kuriyama, Hitoshi, Nonaka, Takashi, Sawatari, Takashi, Tsuboi, Hideo, Akanuma, Masao, Hata, Yasuo
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.05.2005
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Signet Ring Cell - drug therapy; Carcinoma, Signet Ring Cell - secondary; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid - administration & dosage; Paclitaxel - administration & dosage; Peritoneal Neoplasms - secondary; Pyridines - administration & dosage; Quality of Life; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Tegafur - administration & dosage
• ISSN: 0385-0684

The patient was a 49-year-old woman. Chemotherapy was conducted combining paclitaxel (TXL) and TS-1 under the diagnosis of non-resectable advanced gastric cancer with peritoneal dissemination. The administration schedule was as follows: 60 mg/m2 of TXL on days 1, 8 and 15 intravenously and 120 mg/day of TS-1/on days 1 5, 8-12, and 15-19 orally. One cycle lasted for 5 weeks. Grade 1 peripheral neuropathy was noted, but no other serious adverse reaction occurred. Ascites fluid was reduced after completion of the 1st cycle, and the therapeutic efficacy was rated as PR. Abdominal fullness was relieved shortly after starting the treatment, making it possible to conduct treatment on an ambulatory basis in the 2nd and subsequent cycles. At present, 6 months after starting chemotherapy, there is no evidence of relapse or adverse reactions that require intervention. Chemotherapy is being continued on an ambulatory basis. Combination of TXL and TS-1 is expected to show good therapeutic efficacy and improve patients' QOL in patients with gastric cancer associated with peritoneal dissemination.